Supplementary Table S3 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I Study
Open Access
- 1 August 2025
- other
- Published by American Association for Cancer Research (AACR)